<DOC>
	<DOCNO>NCT00452777</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerability BVT.115959 diabetic patient neuropathic pain either analgesia stable analgesia month prior enter study .</brief_summary>
	<brief_title>Efficacy Tolerability Novel A2A Agonist Treatment Diabetic Neuropathic Pain</brief_title>
	<detailed_description>The plan study exploratory study aim provide proof efficacy BVT.115959 reduction symptom pain . Thus , primary objective evaluate anticipate analgesic property BVT.115959 patient diabetic neuropathic pain confirm activity placebo . The study evaluate efficacy tolerability oral BVT.115959 7 mg administer three time day ( t.i.d . ) versus match placebo diabetic patient neuropathic pain either analgesia stable analgesia month prior enter study maintain stable analgesia throughout study . Eligible subject randomize ratio 2:1 ( BVT.115959 : placebo ) . The study consist 1-week screening/baseline period , 4-week treatment period 1 week follow-up period .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<criteria>A diagnosis type 1 2 diabetes mellitus document painful , symmetrical , sensorimotor polyneuropathy least 6 month Either analgesic medication stable analgesic medication least 4 week Female patient fertile childbearing potential Clinically significant unstable hepatic , respiratory , renal , hematologic , cardiovascular peripheral vascular disease Painful condition may confound evaluation neuropathic pain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Diabetic neuropathy , painful</keyword>
	<keyword>Adenosine A2A receptor</keyword>
</DOC>